Search Results - "von Hofe, E"

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence by Mittendorf, E.A., Ardavanis, A., Symanowski, J., Murray, J.L., Shumway, N.M., Litton, J.K., Hale, D.F., Perez, S.A., Anastasopoulou, E.A., Pistamaltzian, N.F., Ponniah, S., Baxevanis, C.N., von Hofe, E., Papamichail, M., Peoples, G.E.

“…AE37 is the Ii-Key hybrid of the MHC class II peptide, AE36 (HER2 aa:776–790). Phase I studies showed AE37 administered with granulocyte macrophage…”
Get full text

Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs by WHITE, D. G, MANEEWANNAKUL, K, VON HOFE, E, ZILLMAN, M, EISENBERG, W, FIELD, A. K, LEVY, S. B

“…Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon…”
Get full text

Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4+ T cell responses by Wambre, E., Bonvalet, M., Bodo, V. B., Maillère, B., Leclert, G., Moussu, H., Von Hofe, E., Louise, A., Balazuc, A.-M., Ebo, D., Hoarau, C., Garcia, G., Van Overtvelt, L., Moingeon, P.

“…Cite this as: E. Wambre, M. Bonvalet,V. B. Bodo, B. Maille`re, G. Leclert,H. Moussu, E. Von Hofe, A. Louise,A.‐M. Balazuc, D. Ebo, C. Hoarau,G. Garcia, L. Van…”
Get full text

Recognition of Ii-Key/MHC class II epitope hybrids derived from proinsulin and GAD peptides by T cells in type 1 diabetes by Vadacca, M, Valorani, M G, von Hofe, E, Kallinteris, N L, Buzzetti, R, Pozzilli, P

“…In order to determine whether the Ii-Key technology can enhance the presentation of specific epitopes associated with type 1 diabetes, we have designed and…”
Get more information

Sensitization of multidrug-resistant human leukemia cells with MDR1-targeted antisense and inhibition of drug-mediated MDR1 induction by LI, X, SMYTH, A. P, BARRETT, D. J, IVY, S. P, VON HOFE, E

“…Increased expression of MDR1 is strongly implicated in the appearance of chemotherapeutic drug resistance in cancer, especially hematological malignancies. We…”
Get full text

Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide by Humphreys, R.E., Adams, S., Koldzic, G., Nedelescu, B., von Hofe, E., Xu, M.

“…We previously found that peptide Ii77-92 from the immunoregulatory Ii protein significantly enhances the binding of antigenic peptides to MHC class II…”
Get full text

POD-04.04: Phase I Clinical Study of the Novel LI-Key/HER-2(776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer by Bisias, S, Georgakopoulou, K, Rempelakos, A, Koutsiaris, E, Papas, A, Arvanitakis, T, Kalinteris, N, Von Hofe, E, Baxevanis, C, Thanos, A

Get full text

MHC Class II Allosteric Site Drugs: New Immunotherapeutics for Malignant, Infectious and Autoimmune Diseases by Xu, M., Li, J., Gulfo, J. V., Von Hofe, E., Humphreys, R. E.

“…The discovery of the interactions of the ‘Ii‐Key’ segment of the Ii protein with the major histocmpatibility complex (MHC) Class II allosteric site, which is…”
Get full text

Relationship Between O6-Alkylguanine-DNA Alkyltransferase Activity and N-Methyl-N'-Nitro-N-Nitrosoguanidine-Induced Mutation, Transformation, and Cytotoxicity in C3H/10T1/2 Cells Expressing Exogenous Alkyltransferase Genes by von Hofe, Eric, Fairbairn, Leslie, Margison, Geoffrey P.

“…While a great deal of evidence has directly implicated the importance of O6-alkylation of guanine in the mutagenicity of alkylating agents, evidence…”
Get full text

Single cell assessment of allergen-specific T cell responses with MHC class II peptide tetramers: methodological aspects by Wambre, Erik, Van Overtvelt, Laurence, Maillère, Bernard, Humphreys, Robert, von Hofe, Eric, Ferhat, Lydia, Ebo, Didier, Moingeon, Philippe

“…We report herein critical methodological principles for assessing, at a single cell level, allergen-specific T cell responses using MHC class II peptide…”
Get more information

Modulation of mouse fibroblast adipocyte differentiation by X-rays and TPA by von Hofe, E, Kennedy, A R

“…The purpose of this study was to determine whether X-rays and the tumor promoter TPA which, in combination, are more effective at transforming cells in vitro…”
Get more information

Interim Analysis of a Randomized Phase II Study of the Novel Ii-Key Hybrid HER2/ Neu Peptide (AE37) Vaccine To Prevent Breast Cancer Recurrence: United States Military Cancer Institute Clinical Trials Group Study I-05 by Peoples, G., Perez, S., Clifton, G., Holmes, J., Georgakopoulou, K., Benavides, L., Gates, J., von Hofe, E., Baxevanis, C., Mittendorf, E., Ardavanis, A., Ponniah, S., Papamichail, M.

“…BACKGROUND: CD4+ T helper peptides from HER2/neu have been evaluated in vaccine trials. The Ii-Key addition, a 4-amino-acid (LRMK) modification, increases…”
Get full text

Ii-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors by Sotiriadou, Nectaria N, Kallinteris, Nikoletta L, Gritzapis, Angelos D, Voutsas, Ioannis F, Papamichail, Michael, von Hofe, Eric, Humphreys, Robert E, Pavlis, Theodoros, Perez, Sonia A, Baxevanis, Constantin N

“…We have demonstrated that coupling an immunoregulatory segment of the MHC class II-associated invariant chain (Ii), the Ii-Key peptide, to a promiscuous MHC…”
Get full text

Results from the first phase I clinical study of the novel Ii-Key/HER2/neu(776–790) hybrid peptide vaccine in patients with prostate cancer by Perez, S. A., Bisias, S., Kallinteris, N. L., Ardavanis, A., Georgakopoulou, K. G., Apostolikas, N., Thanos, A., Papamichail, M., von Hofe, E., Baxevanis, C. N.

“…Abstract only 3011 Background: HER-2/neu(776–790) represents an immunogenic epitope from the HER-2/neu oncoprotein whose immunogenicity is highly potentiated…”
Get full text

Inhibition of X-Ray-Induced Exencephaly by Protease Inhibitors by von Hofe, Eric, Brent, Robert, Kennedy, Ann R.

“…We report that protease inhibitors can reduce the incidence of radiation-induced exencephaly in mice. Previous studies from this and other laboratories have…”
Get full text

Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03 by Benavides, L. C., Holmes, J. P., Gates, J. D., Carmichael, M. G., Hueman, M. T., Mittendorf, E. A., von Hofe, E., Ponniah, S., Peoples, G. E.

“…Abstract only…”
Get full text

Inhibition of Tumorigenesis by a Cytosine-DNA, Methyltransferase, Antisense Oligodeoxynucleotide by Ramchandani, Shyam, MacLeod, A. Robert, Pinard, Marc, Von Hofe, Eric, Szyf, Moshe

“…This paper tests the hypothesis that cytosine DNA methyltransferase (DNA MeTase) is a candidate target for anticancer therapy. Several observations have…”
Get full text

Circulating regulatory (CD4+CD25+FOXP3+) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/ neu peptide (AE37) by Gates, JD, Benavides, LC, Carmichael, MG, Hueman, MT, Holmes, JP, Khoo, S, Stojadinovic, A, von Hofe, E, Ponniah, S, Peoples, GE

“…Abstract #3134 Background: CD4+CD25+FOXP3+ regulatory T cells (Tregs) have been implicated in the suppression of immune responses against various tumors. To…”
Get full text

Interorgan shift of nitrosamine metabolism by dietary ethanol by Wiestler, O D, von Deimling, A, von Hofe, E, Schmerold, I, Wiestler, E, Kleihues, P

Get more information

Delayed cure of Cushing's disease after transsphenoidal surgery of pituitary microadenomas. Report of two cases by McDonald, S D, Von Hofe, S E, Dorfman, S G, Jordan, R M, LaMorgese, J R, Young, R L

“…Transsphenoidal microdissection has been proposed as a preferred means of treating Cushing's disease. This procedure allows the surgeon to remove a pituitary…”
Get more information